A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Mexiletine During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 [The MIND Study]

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 09 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mexiletine (Primary)
Indications Myotonia; Myotonic dystrophy
Focus Adverse reactions; Therapeutic Use
Acronyms MIND Study
Sponsors Lupin

Most Recent Events

03 May 2024 Planned End Date changed from 12 Jul 2024 to 12 Aug 2024.
03 May 2024 Planned primary completion date changed from 31 May 2024 to 1 Jul 2024.
03 May 2024 Planned initiation date changed from 6 Aug 2023 to 3 Sep 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight